Is Biotechnology keeping its promises - PowerPoint PPT Presentation


PPT – Is Biotechnology keeping its promises PowerPoint presentation | free to view - id: f5391-ZDc1Z


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation

Is Biotechnology keeping its promises


'Is Biotechnology keeping its promises. EuropaBio' Dr. Johan VANHEMELRIJCK ... Photosynthesis. 10. Economy: EUR 11 - 22 billion annual added value by 2010 ... – PowerPoint PPT presentation

Number of Views:19
Avg rating:3.0/5.0
Slides: 32
Provided by: ALT89


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Is Biotechnology keeping its promises

Is Biotechnology keeping its promises EuropaBio
Dr. Johan VANHEMELRIJCK Secretary General of
EuropaBio http//
IGBF2 Greece 1-3 July 2005
EuropaBio ? European association of
biotechnology industries (b. 1996) ? About
60 corporate members plus 25 national member
associations representing over 1500
entrepreneurial companies ? Also open to service
companies, research institutions, bioregions
etc. as associate members ? Active in all
sectors healthcare, agro, food, industrial
biotech, environment, young business
European Biotech SMEs A comparison of Industry
European Biotech SMEs A comparison of Finance
European Biotech SMEs A comparison of Growth
European biotech SMEs in 6-15 ageband are at
substantial disadvantage to their American
European Biotech SMEs A comparison of Growth (RD
Initial differences between US and European
biotech SMEs are small. However, those
differences increase rather than shrink with age.
Biotechnology areas
  • EuropaBio members are involved in three main
    biotech areas
  • Industrial biotech / White
  • Healthcare biotech / Red
  • Plant biotech / Green

Industrial or White biotechnology
  • The replacement of fossil fuel by renewable raw
    materials (biomass).
  • The replacement of a conventional,
    non-biological process by one based on
    biological systems, such as whole cells or
    enzymes, used as reagents or catalysts
  • The development of new bioproducts and biofuel

Global Carbon Cycle (Narayan, 2002)

Economy EUR 11 - 22 billion annual added value
by 2010
  • McKinsey estimate of annual added value by the
    global chemical industry
  • EUR billions
  • Impact of white biotechnology
  • Cost reduction
  • 11 - 22
  • Raw materials
  • Process costs
  • Investments
  • 6 - 12
  • Additional revenues
  • 5 - 10
  • New products
  • Value-added processes

Industrial biotechnology impact on
Other studies the Öko-Institute
The report can be consulted at
Healthcare or Red Biotechnology
  • A fast growing field within modern medicine
  • In human health, the benefits of biotechnology
    are evident and the prospects are bright.
    Solutions for diseases which so far have been
    incurable will in great part be due to the
    revolution that biotechnology brings.

What is Healthcare Biotech?
  • Tools to support the human body to utilize its
    own capacities to fight infectious or cancerous
  • Opening new possibilities to prevent, treat and
    cure with novel methods of treatment and
    diagnosis, such as
  • Production of new Medicines and Vaccines
  • Development of peptides and monoclonal
  • Genetic diagnostics
  • Gene therapy
  • Stem cell research
  • Cloning
  • Xenotransplantation
  • …

Why Healthcare Biotech is important ?
  • To meet unmet medical needs with innovative
  • -treatments available for just 10 000 of the 30
    000 known
  • diseases.
  • -increase in the number of disease targets for
  • drug therapy from 500 today to nearly 10 000 in
    the future.
  • -20-30 million Europeans affected by 5000 rare
  • powerful tools to develop diagnostics and
    treatments for orphan
  • diseases.
  • To make medical treatment more comprehensive and
    highly individualized with tailor-made medicines.
  • To move from treatment towards disease prevention
    and cure with improvements in diagnosis.

Why Healthcare Biotech is important ?
Biotechnology protects, relieves and cures
  • Solutions for unmet medical needs
  • More targeted and specific drugs
  • Fewer side-effects
  • Optimisation of known therapies
  • New production techniques
  • Improved diagnostic, toward personalised medicine

? The Bioimpact Study
  • Bioimpact study presents evidences about
    benefits of biotechnology and pharmaceutical
    innovation on public health (patients/society)
    10 diseases,10 biotech drugs
  • Bioimpact is based on the best available
    scientific data but is also written in terms
    accessible to non-specialists
  • Bioimpact was performed by independent medical
    experts from France and UK

  • BioImpact 10 drugs and pathologies Over 1
    billion patients in the world Target population
    almost 1 million people in France

Biotechnology for Inflammatory Diseases
  • Rheumatoid arthritis, Crohns disease
  • 1 of the worldwide population
  • 50 of patients unable to carry out full time

What is Plant or Green biotech?
  • Plant Biotechnology is a rapidly expanding area
    within the field of modern biotechnology
  • Plant Biotechnology can be described as the
    application of science to study plants and
    develop tools that enable the sustainable use of
    plants for food production, feed production and
    the production of other non-food/feed renewable
  • As is the case in modern biotechnology generally,
    the recent, rapid advances in mapping genomes
    together with our growing understanding of gene
    function, protein structure, etc., provide new
    tools for the breeding of crop plants, fruits and
    vegetables and trees that provide us with
    necessary resources in an environmentally
    responsible and sustainable way
  • One of the techniques of modern plant
    biotechnology is genetic manipulation (GM) also
    known as genetic engineering. This is the
    manipulation of genes at the level of the
    chromosome base pairs. It can include the
    introduction of foreign genes into the plant of
    interest thus achieving desired characteristics
    not easily achieved using other means

Why is Green biotechnology important?
  • Modern Plant Biotechnology is a tool that can be
    effectively used to
  • Improve sustainable agronomy (the growing of the
  • by resisting insect pests, fungal, bacterial and
    viral diseases, competing better with weeds etc.
    while using fewer inputs and sprays
  • by changing cropping practices so reducing soil
    erosion, reducing energy (fossil fuel) use and
    greenhouse gas emissions
  • by enabling plants to grow in stressful
    conditions while using available nutrients more
  • etc.

Why is Green biotechnology important?
  • Modern Plant Biotechnology is a tool that can be
    effectively used to
  • Improve sustainable agronomy (the growing of the
  • Assist with improving and diversifying the
    products derived from plants
  • by improving the starch, protein and oil products
    derived from our traditional plants
  • by using plants to provide feeder stocks for
    industrial process (e.g., providing plastics,
    renewable energy, etc.)
  • by enabling plants to produce high value products
    (e.g., functional foods, nutraceuticals,
    pharmaceuticals, etc.)
  • etc.

Europabio Mission Statement EuropaBios mission
is to promote an innovative and dynamic
biotechnology based industry in Europe. We
advocate free and open markets and the removal of
barriers to competitiveness with other areas of
the world. We champion the responsible use of
biotechnology to ensure that its potential is
fully used to the benefit of humans and their
environment. We are committed to an open,
informed dialogue with all stakeholders about the
ethical, social and economic aspects of
biotechnology and its applications.

  • Biotechnology Market Potential
  • An ever-growing cake, but what size is Europes
    slice ?
  • ? worldwide, by 2010, over 2000 billion worth
  • products and services will be biotech,
  • derived or biotech-processed
  • ? worldwide, by 2010, biotech will create 3
  • new jobs (direct indirect)
  • ? already now, over half of medicines in clinical
  • trials (the drugs of tomorrow) are of biotech
  • European Commission estimate Jan. 2002

Analysis of the Core Problem Underperformance in
  • Three key factors including
  • Fragmentation in the marketplace
  • VC investments being spread too thinly across too
    many companies
  • Fragmentation in the capital markets, and the
    corresponding lack of a pan-European.

Analysis of the Core Problem Fragmentation in
the Marketplace
  • No single European Market
  • National origins come before status as Europeans
  • Each country maintains its own regulations,
    language, and cultural norms
  • Lack of centers of critical mass equivalent to
    Silicon Valley and Boston
  • Local markets are small growing beyond them
    requires knowledge of foreign language,
    regulation and market preferences

Analysis of the Core Problem Fragmentation in
the Marketplace
  • Talent is less mobile
  • Cultural presents challenges, Starbucks in UK,
    but not in Italy
  • Growing a technology company in Europe to the
    level of a global competitor can be very
  • In contrast, the US is a market of 290 million,
    one language, one fed. government

Europes Ambitions The Lisbon Targets for 2010
  • ? In April 2000, the European Council (all EU
    government leaders) declared that Europe was to
    become the most competitive and dynamic
    knowledge-based economy in the world by 2010.
  • ? This implied net creation of 15 mio. new jobs
    and increasing labour participation from about
    60 to 70 (the stable US rate)
  • New technologies and biosciences in particular,
    were to play key role in reaching these targets.
  • In 2002 (Barcelona), the European Council added a
    specific RD target increase spending from 1.9
    of GDP to 3 of GDP

What European biotech needs ? stimulating
measures, with fast effect, for young innovative
enterprises (e.g. Young Innovative Company
tax status in France) ? harmonised EU-wide
capital market rules, leading to a single
European venture capital and stock market ?
public money to encourage matching private
funding for early rounds of financing ? high
rewards for high risks, through incentives and
benefits ? successful projects, companies and
entrepreneurs to act and be mediatised as
champions and role models

  • What European biotech needs
  • ? science made more attractive for students
    business made more attractive for scientists
  • ? scientists trained to explain (not defend)
    their work to the public
  • ? simple, stable, enabling regulations
  • ? a strong political leadership, at EU but even
    more at
  • national level
  • ? a solid alliance among the most determined
  • States, to lead the effort and make others

A few interesting websites
EU Institutions http//
/index_en.htm Biotechnology at the European
commission http//
/introduction_en.html UK Report  BioSciences
2015  http// Frenc
h Report on Young Innovative Company
Status http//
plateGenerique.asp?ID_DOC551 EuropaBio website